Scholarlink

Background <p>CDK4/6 inhibitors have transformed treatment for HR + HER2 − advanced breast cancer (aBC). However, adverse events (AEs) often lead to dose adjustments or discontinuation, potentially impacting outcomes. This study assessed AE incidence and its effect on survival in patients receiving abemaciclib (AB), ribociclib (RB), or palbociclib (PB).</p> Methods <p>A retrospective study of 162&#xa0;h + HER2 − aBC patients treated with CDK4/6 inhibitors as first-line therapy (July 2017–September 2024) was conducted. AE incidence, progression-free survival (PFS), and overall survival (OS) were analyzed.</p> Results <p>Most patients (91.4%) were postmenopausal, with a median follow-up of 24.6 months. AEs occurred in 87% of patients, with grade 3–4 neutropenia most common in PB (79.3%) and RB (80%), while AB caused more diarrhea (66.7%). Dose reductions due to AEs were linked to significantly longer PFS (38.5 vs. 16.3 months, <i>p</i> &lt; 0.001) and OS (NR vs. 32.4 months, <i>p</i> = 0.024). Treatment discontinuation was highest for PB (19.6%), followed by RB (16.9%) and AB (14.9%).</p> Conclusions <p>CDK4/6 inhibitors have distinct toxicity profiles. Effective AE management and dose adjustments are crucial for maintaining efficacy, emphasizing the need for AE prediction models to optimize CDK4/6i use in HR + HER2 − aBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Martina Catalano,
  • Gestiana Cekrezi,
  • Irene De Gennaro Aquino,
  • Delia Ravizza,
  • Alexandra Paulet,
  • Kristian Shtembari,
  • Claudia De Angelis,
  • Roberto Petrioli,
  • Daniele Generali,
  • Giandomenico Roviello

摘要

Background

CDK4/6 inhibitors have transformed treatment for HR + HER2 − advanced breast cancer (aBC). However, adverse events (AEs) often lead to dose adjustments or discontinuation, potentially impacting outcomes. This study assessed AE incidence and its effect on survival in patients receiving abemaciclib (AB), ribociclib (RB), or palbociclib (PB).

Methods

A retrospective study of 162 h + HER2 − aBC patients treated with CDK4/6 inhibitors as first-line therapy (July 2017–September 2024) was conducted. AE incidence, progression-free survival (PFS), and overall survival (OS) were analyzed.

Results

Most patients (91.4%) were postmenopausal, with a median follow-up of 24.6 months. AEs occurred in 87% of patients, with grade 3–4 neutropenia most common in PB (79.3%) and RB (80%), while AB caused more diarrhea (66.7%). Dose reductions due to AEs were linked to significantly longer PFS (38.5 vs. 16.3 months, p < 0.001) and OS (NR vs. 32.4 months, p = 0.024). Treatment discontinuation was highest for PB (19.6%), followed by RB (16.9%) and AB (14.9%).

Conclusions

CDK4/6 inhibitors have distinct toxicity profiles. Effective AE management and dose adjustments are crucial for maintaining efficacy, emphasizing the need for AE prediction models to optimize CDK4/6i use in HR + HER2 − aBC.